S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Alibaba Unveils Its Spin-Off Plans
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
The Most Upgraded Stocks From The Q1 Earnings Season
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Can the Dow's 2023 Runaway Winners Keep Running?
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
Laser breakthrough could send stock soaring 2,467% (Ad)
Can These Two Crypto Stocks Stage a Comeback?
Advance Auto Parts Backfires: Is This A Warning For The S&P 500?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Alibaba Unveils Its Spin-Off Plans
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
The Most Upgraded Stocks From The Q1 Earnings Season
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Can the Dow's 2023 Runaway Winners Keep Running?
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
Laser breakthrough could send stock soaring 2,467% (Ad)
Can These Two Crypto Stocks Stage a Comeback?
Advance Auto Parts Backfires: Is This A Warning For The S&P 500?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Alibaba Unveils Its Spin-Off Plans
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
The Most Upgraded Stocks From The Q1 Earnings Season
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Can the Dow's 2023 Runaway Winners Keep Running?
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
Laser breakthrough could send stock soaring 2,467% (Ad)
Can These Two Crypto Stocks Stage a Comeback?
Advance Auto Parts Backfires: Is This A Warning For The S&P 500?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Alibaba Unveils Its Spin-Off Plans
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
The Most Upgraded Stocks From The Q1 Earnings Season
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Can the Dow's 2023 Runaway Winners Keep Running?
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
Laser breakthrough could send stock soaring 2,467% (Ad)
Can These Two Crypto Stocks Stage a Comeback?
Advance Auto Parts Backfires: Is This A Warning For The S&P 500?
NASDAQ:VERU

Veru (VERU) Competitors

$0.99
-0.09 (-8.33%)
(As of 05/31/2023 ET)
Compare
Today's Range
$0.99
$1.09
50-Day Range
$0.99
$1.49
52-Week Range
$0.93
$24.55
Volume
4.55 million shs
Average Volume
2.55 million shs
Market Capitalization
$88.35 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.67

VERU vs. NATR, SPRB, BLRX, LPTX, GALT, DBTX, ARAV, ANIX, ETON, and SPRO

Should you be buying Veru stock or one of its competitors? The main competitors of Veru include Nature's Sunshine Products (NATR), Spruce Biosciences (SPRB), BioLineRx (BLRX), Leap Therapeutics (LPTX), Galectin Therapeutics (GALT), Decibel Therapeutics (DBTX), Aravive (ARAV), Anixa Biosciences (ANIX), Eton Pharmaceuticals (ETON), and Spero Therapeutics (SPRO). These companies are all part of the "pharmaceutical preparations" industry.

Veru vs.

Nature's Sunshine Products (NASDAQ:NATR) and Veru (NASDAQ:VERU) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, earnings, dividends, community ranking, profitability, valuation and risk.

75.2% of Nature's Sunshine Products shares are owned by institutional investors. Comparatively, 48.9% of Veru shares are owned by institutional investors. 5.4% of Nature's Sunshine Products shares are owned by insiders. Comparatively, 23.9% of Veru shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Veru received 106 more outperform votes than Nature's Sunshine Products when rated by MarketBeat users. Likewise, 69.21% of users gave Veru an outperform vote while only 62.80% of users gave Nature's Sunshine Products an outperform vote.

CompanyUnderperformOutperform
Nature's Sunshine ProductsOutperform Votes
157
62.80%
Underperform Votes
93
37.20%
VeruOutperform Votes
263
69.21%
Underperform Votes
117
30.79%

In the previous week, Nature's Sunshine Products' average media sentiment score of 1.91 beat Veru's score of 0.00 indicating that Nature's Sunshine Products is being referred to more favorably in the media.

Company Overall Sentiment
Nature's Sunshine Products Very Positive
Veru Neutral

Nature's Sunshine Products has higher revenue and earnings than Veru. Veru is trading at a lower price-to-earnings ratio than Nature's Sunshine Products, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nature's Sunshine Products$421.91 million0.50-$390 thousand$0.1765.76
Veru$39.35 million2.25-$83.78 million-$1.73-0.57

Nature's Sunshine Products currently has a consensus price target of $15.00, indicating a potential upside of 34.17%. Veru has a consensus price target of $13.67, indicating a potential upside of 1,280.47%. Given Veru's higher possible upside, analysts plainly believe Veru is more favorable than Nature's Sunshine Products.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nature's Sunshine Products
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Veru
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

Nature's Sunshine Products has a beta of 0.84, indicating that its share price is 16% less volatile than the S&P 500. Comparatively, Veru has a beta of -0.22, indicating that its share price is 122% less volatile than the S&P 500.

Nature's Sunshine Products has a net margin of 0.81% compared to Veru's net margin of -652.36%. Nature's Sunshine Products' return on equity of 4.14% beat Veru's return on equity.

Company Net Margins Return on Equity Return on Assets
Nature's Sunshine Products 0.81% 4.14% 2.61%
Veru -652.36% -206.09% -115.37%

Summary

Nature's Sunshine Products beats Veru on 10 of the 16 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VERU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VERU vs. The Competition

MetricVeruPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$88.35M$5.73B$4.51B$6.12B
Dividend YieldN/A2.71%2.32%6.16%
P/E Ratio-0.579.75128.2214.36
Price / Sales2.25322.263,636.9386.59
Price / CashN/A20.5595.84107.29
Price / Book5.215.155.037.11
Net Income-$83.78M$189.25M$117.75M$193.34M
7 Day Performance-3.88%1.05%0.17%0.50%
1 Month Performance-26.12%1.12%0.41%1.07%
1 Year Performance-91.88%19.92%21.61%0.14%

Veru Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NATR
Nature's Sunshine Products
2.4388 of 5 stars
$11.14
+1.3%
$15.00
+34.6%
-7.5%$212.22M$421.91M65.53850Positive News
SPRB
Spruce Biosciences
2.2174 of 5 stars
$2.40
-1.2%
$7.60
+216.7%
+55.8%$96.58M$1.96M-1.2915Positive News
BLRX
BioLineRx
1.6798 of 5 stars
$1.57
+4.7%
$6.00
+282.2%
+1.0%$96.60MN/A-2.8538Analyst Revision
LPTX
Leap Therapeutics
1.7456 of 5 stars
$0.81
+17.4%
$2.80
+245.7%
-17.6%$96.72M$1.50M-1.1436
GALT
Galectin Therapeutics
1.6525 of 5 stars
$1.61
+0.6%
$11.00
+583.2%
+21.7%$95.73MN/A-2.406Positive News
DBTX
Decibel Therapeutics
2.3555 of 5 stars
$3.90
-0.3%
$9.25
+137.2%
+83.6%$97.54MN/A-1.5762Short Interest ↓
Positive News
Gap Down
ARAV
Aravive
1.9528 of 5 stars
$1.63
+3.2%
$8.50
+421.5%
+29.8%$97.55M$9.54M-0.7317Gap Up
High Trading Volume
ANIX
Anixa Biosciences
2.0753 of 5 stars
$3.16
-1.9%
$10.50
+232.3%
-14.8%$97.71M$510,000.00-7.714Gap Up
ETON
Eton Pharmaceuticals
1.9744 of 5 stars
$3.86
flat
$10.00
+159.1%
+30.3%$98.45M$24.38M-16.0817Short Interest ↓
Positive News
High Trading Volume
SPRO
Spero Therapeutics
2.4717 of 5 stars
$1.77
flat
$7.00
+295.5%
+47.5%$93.05M$54.00M-1.97146Positive News
Gap Up

Related Companies and Tools

This page (NASDAQ:VERU) was last updated on 6/1/2023 by MarketBeat.com Staff

My Account -